Skip Navigation

Annals of Oncology 2006 17(3):361-371; doi:10.1093/annonc/mdj052
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow CME/CE:
Take the course for this article:
 Annals of Oncology course: part 4 iss...
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (13)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Glynne-Jones, R.
Right arrow Articles by Sebag-Montefiore, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Glynne-Jones, R.
Right arrow Articles by Sebag-Montefiore, D.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 European Society for Medical Oncology

review

The integration of oral capecitabine into chemoradiation regimens for locally advanced rectal cancer: how successful have we been?

R. Glynne-Jones1,*, J. Dunst2 and D. Sebag-Montefiore3

1 Mount Vernon Cancer Centre, Northwood, London, UK; 2 Martin Luther University, Halle, Germany; 3 Leeds Cancer Centre, Cookridge Hospital, Leeds, UK

* Correspondence to: Dr R. Glynne-Jones, Mount Vernon Cancer Centre, Northwood, Middlesex, London, HA6 2RN, UK. Tel: +44-1923-844767; Fax: +44-1923-844840; E-mail: rob.glynnejones{at}nhs.net

The aim was to review available literature on capecitabine-based chemoradiation regimens for the preoperative treatment of patients with locally advanced rectal cancer (LARC) and determine efficacy and safety data for capecitabine in this setting. Medical literature databases (Pubmed, Medline) and abstracts/posters presented at recent scientific congresses (ASCO, ASTRO, ESTRO and ECCO) were screened and critically analysed to identify relevant data. A number of phase I/II studies have demonstrated that capecitabine is effective and well tolerated in combination with preoperative radiotherapy in patients with LARC. Phase III studies are ongoing. Continuous oral administration of capecitabine (825 mg/m2 twice daily for 7 days/week) is an effective regimen and has similar tolerability to the less dose-intensive intermittent regimens of capecitabine given 5 days/week followed by 2 day's rest or 14 days followed by 7 day's rest as used in systemic chemotherapy for patients with colorectal or breast cancer. Capecitabine chemoradiation is associated with a relatively low rate of grade 3/4 adverse events. Capecitabine simplifies chemoradiation and provides a convenient treatment option for both patients and health care professionals. Combining capecitabine with cytotoxic agents such as oxaliplatin and irinotecan has the potential to further improve antitumour efficacy in patients receiving preoperative chemoradiation. Data from phase I/II single-agent and combination capecitabine chemoradiation studies provide a clear rationale for replacing infusional 5-FU with oral capecitabine as part of chemoradiation for patients with LARC.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
E. Casado, P. Pfeiffer, J. Feliu, M. Gonzalez-Baron, L. Vestermark, and H. A. Jensen
UFT (tegafur-uracil) in rectal cancer
Ann. Onc., April 1, 2008; (2008) mdn067v1.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
C. Aschele and S. Lonardi
Multidisciplinary treatment of rectal cancer: medical oncology.
Ann. Onc., November 1, 2007; 18(11): 1908 - 1915.
[Full Text] [PDF]

Home page
 The OncologistHome page
R. Glynne-Jones and M. Harrison
Locally Advanced Rectal Cancer: What Is the Evidence for Induction Chemoradiation?
Oncologist, November 1, 2007; 12(11): 1309 - 1318.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. Rodel, T. Liersch, R. M. Hermann, D. Arnold, T. Reese, M. Hipp, A. Furst, N. Schwella, M. Bieker, G. Hellmich, et al.
Multicenter Phase II Trial of Chemoradiation With Oxaliplatin for Rectal Cancer
J. Clin. Oncol., January 1, 2007; 25(1): 110 - 117.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
H.-J. Schmoll and D. Arnold
Update on Capecitabine in Colorectal Cancer
Oncologist, October 1, 2006; 11(9): 1003 - 1009.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.